Nanoviricides, Inc., a company specializing in broad spectrum antivirals, announced promising results for its NV-387 medication. Designed to combat multiple viral infections, its many indications are supported by recent animal studies. Among these, its effectiveness against flu, coronavirus, measles and pandemics such as mpox and smallpox.
The company plans to accelerate the approval process through various regulatory routes, including obtaining the status of an orphan medication. The promising profile of the NV-387 positions it as a basic potential element in pandemic preparation strategies, including its adaptability to HSPG viruses, a current cell molecule.
Nanoviricides aims to launch phase II tests for MPOX, which could prove to be crucial in the response to the pandemic. The company considers NV-387 as an essential tool for global health, strengthening defenses against viral threats while potentially guaranteeing early income thanks to priority examination vouchers.
R. E.
